BioEclipse Therapeutics, Inc.
Formerly ConcentRx, Inc.
Funding rounds
1 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Jun 2019 | $10 M | No. 1 | $10 to $50 million | equity, options | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
BioEclipse Therapeutics, Inc. reported no revenue for its most recent fiscal year (filed Apr 2022).
SEC Form C/A · Apr 2022
Net loss for the same year: $4.39 million.
SEC Form C/A · Apr 2022
BioEclipse Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Oct 2019).
SEC Form D · Oct 2019
The industry group it chose in its notices: Biotechnology.
SEC Form D · Oct 2019
In its own words
How the company describes itself to search engines on its website, word for word.
“BioEclipse Therapeutics™ is a clinical-stage oncology company that uses its proprietary technology to develop the next generation of immuno-oncology therapeutics.”
Source: The company's website · as of Nov 15, 2026
Products and services#
No products or services on record: its website does not describe any in structured form (a page that declares itself a product or service), and Wikidata lists none.
Investors#
No investor of BioEclipse Therapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 13 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Benjamin Carter | Executive officer | Oct 2019 |
| Pamela Reilly Contag | Executive officer | Oct 2019 |
| Stephen Thau | Executive officer | Oct 2019 |
| Pamela Contag | Executive officer | Jun 2019 |
| Biao He | Director | Oct 2019 |
| Catherine Sohn | Director | Oct 2019 |
| Elona Baum | Director | Oct 2019 |
| Gregory Schiffman | Director | Oct 2019 |
| Mark Frohlich | Director | Oct 2019 |
| Pamela Reilly Contag | Director | Oct 2019 |
| Pamela Contag | Director | Jun 2019 |